Reply: Clinical efficacy of lenvatinib for the treatment of radioiodine‐refractory thyroid carcinoma: A systematic review and meta‐analysis of clinical trials.

Defining radioiodine-refractory differentiated thyroid cancer: efficacy and safety of lenvatinib by radioiodine-refractory criteria in the SELECT trial. What's more, Nair's paper, published in 2015, was a summary of the FDA's approval of lenvatinib for radioiodine-resistant thyroid cancer treatment, and the data here were identical to those in the SELECT study. Keywords: lenvatinib; meta-analysis; radioiodine-refractory thyroid carcinoma; systematic review EN lenvatinib meta-analysis radioiodine-refractory thyroid carcinoma systematic review 275 276 2 01/03/23 20230201 NES 230201 We read with great interest the paper by Yan et al., sharing the perspective that lenvatinib is beneficial for the treatment of radioiodine-refractory thyroid cancer in terms of the extension of progression-free survival (PFS) and overall survival (OS).[1] We greatly appreciated the authors' contributions in studying the treatment of thyroid cancer refractory to radioactive iodine, however, it seems to be some critical problems when the authors drew to this conclusion. [Extracted from the article]